Spots Global Cancer Trial Database for Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Study Description

Brief Summary: An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will be assessed in this trial.

Detailed Description: Outline: This is a multi-center study. Patients who meet eligibility criteria will receive treatment as follows until disease progression or excessive toxicities: * Erlotinib 150 mg p.o. daily on days 2-7, 9-14, 16-28 * Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8, 15 Treatment cycle = 28 days Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Life expectancy: At least 12 weeks Hematopoietic: * Absolute neutrophil count (ANC) \> 1000 mm3 * Platelet count \> 75,000 mm3 * Hemoglobin \> 8 g/dL Hepatic: * Bilirubin \< 2.0 x upper limit of normal (ULN) * Transaminases (AST, ALT) \< 5.0 x ULN if alkaline phosphatase is \< 2.5 x ULN, or alkaline phosphatase \< 5 x ULN if transaminases are \< 1.5 x ULN. * If not on anticoagulation: PT \< 4 seconds above ULN; INR \< 1.5; PTT \< 1.3 x ULN. * If on therapeutic anticoagulation, patients may have an INR \> 1.5 and PTT within therapeutic range; INR will be monitored weekly until stable. * Serum Albumin \> 3.0 Renal: * Creatinine clearance of \> 60 ml/ min (by Cockcroft-Gault) Pulmonary: * Not specified

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial